Figure 3.
Panel a shows a single survival curve with cumulative survival on the y-axis (percent) and follow-up time on the x-axis (months). The curve indicates a gradual decline in survival over approximately 250 months. Panel b compares survival between patients with XL-CGD and AR-CGD. The y-axis represents cumulative survival (percent), and the x-axis indicates follow-up time in months. The curve for XL-CGD shows a steeper decline compared to AR-CGD. Panel c compares survival between patients who underwent hematopoietic stem cell transplantation (HSCT) and those who did not. The y-axis represents cumulative survival (percent), and the x-axis indicates follow-up time in months. The curve for patients who underwent HSCT shows better survival rates compared to those who did not.
Survival in patients with CGD. (a) Kaplan–Meier survival curve showing cumulative overall survival of CGD patients during follow-up (up to ∼250 mo). The y-axis represents cumulative survival (%), and the x-axis indicates follow-up time in months. (b) Survival according to inheritance pattern (XL-CGD vs. AR-CGD). Kaplan–Meier survival analysis comparing cumulative survival between patients with XL-CGD and AR-CGD. (c) Survival according to HSCT status. Kaplan–Meier survival curves comparing cumulative survival between CGD patients who underwent HSCT and those who did not. The y-axis represents cumulative survival (%), and the x-axis indicates follow-up time in months (up to ∼250 mo).